Keio multicenter trial in high-dose interferon-α2b treatment for chronic hepatitis C

Hidetsugu Saito, Kanji Tsuchimoto, Shingo Miyaguchi, Shinichiro Tada, Kentaro Sawaguchi, Kohichi Komatsu, Kohtaro Kaneko, Tetsu Watanabe, Toshio Morizane, Hiromasa Ishii

研究成果: Article査読

11 被引用数 (Scopus)

抄録

The efficacy of two different high-dose treatment of IFN-α2b was evaluated in this study. Serum hepatitis C virus (HCV) RNA levels were semi-quantified by simplified reverse transcription polymerase chain reaction. Seventy-one patients with chronic hepatitis C received 10 million units of IFN-α2b daily for 2 weeks or thrice a week for 24 weeks. Alanine aminotransferase (ALT) levels overall normalized in 78.1% and 51.6% of the cases at the end of the therapy and 6 months after that, respectively. HCV RNA disappeared in 71.9% and 35.7% of the patients at the end of the therapy and 6 months after that, respectively. There was no significant difference between the 2 different regimes. The efficacy of the treatment was fair in cases in which the pretreatment level of the viral amount was low. The results of this study indicate that daily administration of IFN in the first 2 weeks during a 6-month course does not increase the efficacy of the therapy in such a high-dose treatment regime.

本文言語English
ページ(範囲)161-167
ページ数7
ジャーナルKeio Journal of Medicine
45
3
DOI
出版ステータスPublished - 1996 9

ASJC Scopus subject areas

  • Medicine(all)

フィンガープリント 「Keio multicenter trial in high-dose interferon-α2b treatment for chronic hepatitis C」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル